Literature DB >> 12363038

An immunohistochemical study of the clearance of apoptotic cellular fragments.

M P G Leers1, V Björklund, B Björklund, H Jörnvall, M Nap.   

Abstract

We investigated the distribution and fate of apoptotic bodies during human development and in the adult, using an antibody (M30) that recognizes a neo-epitope formed early in the apoptotic cascade by caspase cleavage of cytokeratin 18. In the fetus, we found extensive accumulation of M30-positive, non-phagocytosed fragments in the red pulp of the spleen, subcutaneous and submucosal vessels, the interstitium of the lung, and the glomerular mesangium of the kidneys. In the liver, M30-immunoreactive fragments were found inside macrophages in the sinusoids. The number of these fragments and the intensity of the immunostaining increased with the gestational age of the fetus. In the adult, M30-positive fragments were barely detectable in normal tissues. However, many pathological situations, including both chronic degenerative processes and metastatic cancer, were associated with accumulation of M30-positive fragments in the red pulp of the spleen. In the liver and kidney, no fragments could be detected. Remarkably, 13 of the 16 patients with metastasized cancer showed pronounced accumulation of M30-positive fragments containing hematoxylin-reactive material in the red pulp of the spleen. In the non-cancerous cases, such DNA-containing fragments were only seen in 9 of 94 cases. The results show that when apoptotic activity is high, as during development in the fetus or during metastasis and other pathological processes in the adult, the phagocytic clearance of apoptotic bodies can be overloaded. These apoptotic fragments then accumulate in the spleen. The visual detection of apoptotic fragments is concluded to reflect increased cell turnover.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363038     DOI: 10.1007/s00018-002-8513-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  10 in total

Review 1.  The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?

Authors:  Christopher D Gregory; Andrew Devitt
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

Review 2.  Biomarker method validation in anticancer drug development.

Authors:  J Cummings; T H Ward; A Greystoke; M Ranson; C Dive
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 3.  Intermediate filament proteins of digestive organs: physiology and pathophysiology.

Authors:  M Bishr Omary
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-03-30       Impact factor: 4.052

4.  Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.

Authors:  J Cummings; M Zweifel; N Smith; P Ross; J Peters; G Rustin; P Price; M R Middleton; T Ward; C Dive
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

5.  Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

Authors:  J Cummings; T H Ward; E LaCasse; C Lefebvre; M St-Jean; J Durkin; M Ranson; C Dive
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

Review 6.  Clearance of Apoptotic Cells by Tissue Epithelia: A Putative Role for Hepatocytes in Liver Efferocytosis.

Authors:  Scott P Davies; Gary M Reynolds; Zania Stamataki
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

7.  Tools Allowing Independent Visualization and Genetic Manipulation of Drosophila melanogaster Macrophages and Surrounding Tissues.

Authors:  Attila Gyoergy; Marko Roblek; Aparna Ratheesh; Katarina Valoskova; Vera Belyaeva; Stephanie Wachner; Yutaka Matsubayashi; Besaiz J Sánchez-Sánchez; Brian Stramer; Daria E Siekhaus
Journal:  G3 (Bethesda)       Date:  2018-03-02       Impact factor: 3.154

8.  APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Chris Tsopelas; Douglas Smyth; Jim Manavis; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

9.  Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

Authors:  Fares Al-Ejeh; Jocelyn M Darby; Michael P Brown
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

10.  Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization.

Authors:  Éva Kárpáti; Alexandra Papp; Andrea E Schneider; Dávid Hajnal; Marcell Cserhalmi; Ádám I Csincsi; Barbara Uzonyi; Mihály Józsi
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.